Quest Pharmatech Inc logo

QPT - Quest Pharmatech Inc News Story

C$0.16 0.0  0.0%

Last Trade - 07/08/20

Sector
Healthcare
Size
Micro Cap
Market Cap £15.4m
Enterprise Value £15.3m
Revenue £n/a
Position in Universe 1183rd / 2679

BRIEF-Oncoquest Receives "Notice Of Allowance" For Patent Protection Of Administration Schedule Of Oregovomab And Chemotherapy For Stage III-IV Ovarian Cancer Patients

Wed 25th September, 2019 12:14pm
Sept 25 (Reuters) - Quest Pharmatech Inc  QPT.V :
    * ONCOQUEST RECEIVES "NOTICE OF ALLOWANCE" FOR PATENT
PROTECTION
OF THE ADMINISTRATION SCHEDULE OF OREGOVOMAB AND CHEMOTHERAPY
FOR STAGE III-IV OVARIAN CANCER PATIENTS
    * QUEST PHARMATECH - CO IS CURRENTLY PLANNING TO LAUNCH A
PHASE 3
TRIAL FOR OREGOVOMAB IN Q1 2020

Source text for Eikon:  ID:nPn1gxXXHa 
Further company coverage:  QPT.V 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.